Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Research
Combretastatin A4 Prodrug trial indicates antitumor activity
June 16th, 2005
OXiGENE, Inc., (OXGN, OXGN) announced that Combretastatin A4 Prodrug (CA4P), the company's lead vascular targeting agent (VTA), indicated both "antitumor activity" and "no unexpected toxicity" thus far in the phase Ib portion of a planned phase Ib/II combination trial of the compound in patients with advanced cancer. These preliminary findings are described in an abstract entitled "A phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer" published for attendees of the 2005 American Society of Clinical Oncology Annual Meeting taking place in Orlando, Florida. ...
Source: Women's Health Weekly (2005-06-16)
|
